ALAMEDA, Calif.–BioTime, Inc. (NYSE Amex:BTIM) announced today that it has initiated shipments of stem cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement between the two companies that was announced on July 9, 2009. BioTime has shipped inventory of six ACTCellerate™ progenitor cell lines to Millipore and plans to begin shipments of additional cell lines and ESpan™ cell growth media in the next several weeks. Derived from human embryonic stem cells but not fully differentiated into specific cell types, each ACTCellerate™ line provides a convenient, highly purified source of progenitor cells that may have applications in drug discovery, research, and the development of therapeutic products.

“Many researchers prefer to work with well-characterized progenitor cells rather than starting from scratch with embryonic stem cells”

BioTime’s research products will soon be available to be ordered by researchers through Millipore’s stem cell homepage, www.millipore.com/stemcells. Millipore, which is already a leading supplier of stem cell research reagents, plans a full launch for BioTime’s progenitor cell lines and growth media during the first quarter of 2010.

BioTime’s progenitor cell lines and growth media are also being offered through BioTime Asia, Limited as research products to prestigious hospital-based stem cell research centers in the People’s Republic of China.

“Many researchers prefer to work with well-characterized progenitor cells rather than starting from scratch with embryonic stem cells,” said Michael D. West, Ph.D., CEO of BioTime. “The ACTCellerate™ product line allows scientists to save time and money, and to accomplish a wider range of research goals. We look forward to working with Millipore’s outstanding marketing team to make these cell lines widely available to scientists worldwide, allowing them to more quickly perform the research and development work that may lead to life-saving therapies.”

“We are pleased to be entering a new stage in the development of BioTime’s business as we begin to generate revenues not only from Hextend®, our FDA-approved blood plasma volume expander product, and from our CIRM grant, but also from our research products. Our goal is to continue to increase our revenues steadily while also advancing our stem cell therapeutic product development efforts in the U.S. and Asia.”

Background

The ACTCellerate™ lines were developed using a novel approach to stem cell differentiation. Unlike traditional methods that result in low percentages of progenitor cells, the ACTCellerate™ lines are generated using a two-step multiplex process that rapidly isolates and purifies progenitor cells from many different lineages. Each progenitor line is selected for scalability and robustness, and then characterized by phenotype and gene marker expression.

About Millipore

Millipore is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit www.millipore.com.

Millipore is a registered trademark and the “M” logo and ADVANCING LIFE SCIENCE TOGETHER are trademarks of Millipore Corporation.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime’s subsidiary OncoCyte Corporation focuses on the therapeutic applications of stem cell technology in cancer. BioTime also plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia. In addition to its stem cell products, BioTime markets blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment, and other applications. BioTime’s lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com.

Forward Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.